Advanced Cell Technology to Present at Regen Med Investor Day 2013 Business Wire MARLBOROUGH, Mass. -- April 16, 2013 Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present at the Alliance for Regenerative Medicine’s first annual Regen Med Investor Day on Wednesday, April 17, 2013 in New York City. Organized by the Alliance for Regenerative Medicine (ARM) in partnership with financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features 16 of the regenerative medicine field’s leading companies. In addition, there will be disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector, and keynote-style talks by Jeff Jonas, president of Shire Regenerative Medicine, and Kieran Murphy, president and CEO, GE Healthcare Life Sciences. The following are specific details regarding ACT’s presentation at the conference: Event: ACT Presentation at ARM’s Regen Med Investor Day Date: Wednesday, April 17, 2013 Time: 3:45 p.m. EDT Location: Harmonie Club, 4 East 60th Street, New York, NY 10022 A live video webcast of all company presentations will be available at http://alliancerm.org/rmdaywebcast and will also be published on ARM’s website shortly after the event. A copy of Mr. Rabin’s presentation will be available on the presentations section of the ACT website. Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at email@example.com. Please visit http://alliancerm.org/event/regen-med-investor-day for more information. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful. Contact: Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292
Advanced Cell Technology to Present at Regen Med Investor Day 2013
Press spacebar to pause and continue. Press esc to stop.